Abstract
Adenovirus-based vectors are among the most commonly used platforms for gene delivery and gene therapy studies. One of the obstacles for potential application is dose-related toxicity. We show here that adenovirus infection and Ad-mediated gene delivery can be enhanced by inhibitors of bromodomain and extra-terminal (BET) family proteins. We showed that JQ1, but not its inactive enantiomer (−)-JQ1, dose-dependently promoted Ad infection and Ad-mediated gene delivery in both epithelial and lymphocyte cells. Given orally, JQ1 also enhanced transgene expression in a murine tumor model. Inhibitors of histone deacetylases (HDACi) are among the commonly reported small molecule compounds which enhance Ad-mediated gene delivery. We found that JQ1 treatment did not cause histone acetylation nor expression of Ad attachment receptor CAR. Instead, JQ1 treatment induced an increase in BRD4 association with CDK9, a subunit of P-TEFb of transcription elongation. Concurrently, we showed that CDK9 inhibition blocked Ad infection and JQ1 enhancement on the infection. The study exemplifies the potentials of BET inhibitors like JQ1 in oncolytic virotherapy.
Similar content being viewed by others
Introduction
Adenovirus-based vectors are among the most commonly utilized platforms for gene delivery in cell biology studies and in gene therapy applications. Adenoviral vectors are advantageous in that their abilities to achieve a high efficiency of transduction, high levels of gene expression, and to infect non-dividing cells. Ad vectors have been studied extensively in tumor therapy trials1,2. In addition to the use of a conditionally-replicative Ad vector for head and neck cancer in China3, recent approval of an oncolytic herpesvirus-based treatment by the US Food and Drug Administration (FDA) raises optimism on the potential of viral vectors in cancer therapy4.
Significant hurdles exist that prevent the realization of clinic application of Ad vectors. This is primarily because of the preexisting humoral and cellular immunity against common human Ad serotypes. Moreover, adenoviral particles are extremely immunogenic capsids and systemic administration of high doses of adenovirus can lead to systemic inflammatory response, which can be lethal in some extreme cases. The failure in achieving high levels of efficient transduction in target tissues is a limiting factor. Therefore, strategies have been developed for Ad modifications to enhance the efficacy while reducing dose associated toxicity5,6.
The specificity of Ad-mediated gene delivery depends on host cell susceptibility and permissibility for invading virus. The classical model of Ad2/5 infection primarily involves high affinity binding via the capsid fiber protein to the coxsackievirus and adenovirus receptor (CAR)7,8 and subsequent internalization via receptor mediated endocytosis through the capsid penton base and αv integrins9,10, while the in vivo entry pathway remains elusive. It is now widely believed that several circulating blood proteins such as coagulation factors also dictate the specificity of Ad infection11,12,13. Once the virus has successfully entered the host cells, viral DNA is subsequently released to the nuclei for DNA replication. Therefore, strategies targeting virus cell entry stages have been the primary targets to enhance Ad mediated gene delivery efficiency and specificity14.
It is known that viruses utilize host cell translation machinery for protein synthesis, which can be a potential target for enhanced Ad-mediated gene delivery. Adenoviruses encode a highly basic protein called protein VII that resembles cellular histones and affects cellular chromatin15. In the early phases of an infection, the incoming viral DNA is associated with both viral core protein VII and cellular histones. In late phases of infection, newly synthesized viral DNA is also associated with histones and tends to be wrapped in nucleosomes within the host cell nucleus16,17,18,19. The histone tails are subjected to modifications, including acetylation, methylation, phosphorylation, ADP ribosylation, and ubiquitination20. Acetylation of lysine residues within nucleosomal histone tails provides a crucial mechanism for epigenetic control of gene expression. Lysine acetylation is a reversible posttranslational modification catalyzed by histone acetyltransferases (HATs) or removed by histone deacetylases (HDACs). It is known that the adenoviral E1A protein causes significant reduction in cellular levels of lysine acetylation of histone H321,22 and can disturb the normal cellular interaction between p300/CBP and its associated histone acetylase23,24. It is not clear how epigenetic factors may affect adenovirus replication or infection, although limited evidence suggests that histone modification is involved in the regulation of adenovirus gene expression17,25. For example, inhibitors of histone deacetylase (HDACi) have been demonstrated to promote both wild type Ad infection and gene delivery efficiency by replicative defective Ad viruses19,26,27,28.
Lysine acetylation alters the electrostatic properties of histones, and often creates docking sites for bromodomain-containing “reader” proteins. BRD4 is a member of the BET (bromodomain and extra-terminal domain) family protein that is involved in multiple processes of the DNA virus life cycle, including viral replication, genome maintenance, and gene transcription29. BRD4 serves as a ‘reader’ to recognize acetylated lysine in histones and to recruit positive transcriptional elongation factor b (P-TEFb), thereby promoting transcriptional activity and chromatin remodeling30. JQ1 is a BRD4 inhibitor that selectively interacts with the BD1 and BD2 domains of BRD4 and disrupts the interaction of BRD4 protein with acetylated lysine31,32. BRD4 has been shown to regulate HPV and HSV infection, while JQ1 treatment reactivates HIV from latency33,34,35.
In consideration of the significance of histone modifications in gene regulation, we tested whether JQ1 and structurally different BRD4 inhibitors had any effect on Ad infection and Ad-mediated gene delivery. We found that JQ1and PFI-1 promoted Ad infection and Ad-mediated EGFP gene delivery. Here we report the identification of JQ1 as a potent enhancer on Ad infection and Ad-mediated gene delivery.
Materials and Methods
Cells and viruses
Human lung adenocarcinoma A549 epithelial cell line (ATCC, CCL-185), human cervical carcinoma HeLa cell line (ATCC, CCL-2), human acute T cell leukemia Jurkat cell line (ATCC, TIB-152), and murine lymphocytic leukemia P388D1 cell line (ATCC, CCL-46) were purchased from ATCC (Manassas, VA) or from Cell Bank of Chinese Academy of Sciences (Shanghai, China). The cells were cultured in DMEM (high glucose) supplemented with 10% heat-inactivated fetal bovine serum (FBS), sodium pyruvate, non-essential amino acids, and penicillin-streptomycin (all from Life Technologies, Carlsbad, CA) in a humidified incubator with 5% CO2 at 37 °C. Wild type Ad2 was a kind gift from Dr. Glen Nemerow’s lab. The virus was propagated and titrated in A549 cells. Ad-EGFP was generated in the lab using the Ad-Easy system36. The viruses were CsCl gradient purified and dialyzed against Tris-HCl (pH 8.1, 10 mM) buffered saline solution and titrated by plaque forming assay following a reported protocol37.
Reagents and Antibodies
PFI-1, RVX-208, LDC000067 (CDK9 inhibitor)38, and flavoripidol (RNA Pol II inhibitor)39 were purchased from Selleck Chemicals. JQ1 and (−)-JQ1 were purchased from MedChem Express. Antibodies to BRD4 (Abcam, ab128874), CDK9 (Santa Cruz, sc-13130), phospho-histone-3 (Ser10), acetyl-histone-3 (K56) (Beyoyime, Nantong), GAPDH (Bioworld Technology) were obtained commercially. The anti-CAR monoclonal antibody RmcB was from ATCC (CRL-2379). Rabbit antiserum to Ad2 hexon (GenScript, Nanjing), and to Ad2 penton base (ABmart, Shanghai) were prepared using commercial sources. Horse radish peroxidase (HRP)-conjugated secondary antibodies were purchased from Sigma-Aldrich.
Infection assay and drug treatment
For treatment with chemicals, the compounds dissolved in DMSO were first tested on A549 cells to determine a minimal cytotoxicity concentration using an MTT method40. We tested JQ1 on A549 cells by treating the cells with 10, 30, 100, 300, 500 and 1000 nM JQ1 for 48 hr, using 0.1% DMSO as a vehicle control. We used 48 h since most of the infection assays lasted 24–36 hr or less. At up to 500 nM, the treatment did not significantly affect cell viability. At up to 1000 nM, (−)-JQ1, RVX-208, PFI-1 showed no toxic effect to A549 cells after 48 h treatment.
For infections, the cells were plated in culture plates for overnight. The cells were treated at 1 h prior to inoculation or at time points indicated. For immunoblotting assays, the cells were collected and lysed with a buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% NP-40, and a cock-tail of protease inhibitors (Roche). The lysates were separated by SDS PAGE and transferred to PVDF membrane (Millipore) for immunoblotting analysis. GAPDH was used as a loading control. The images were captured using a ChemiScope imaging system (Shanghai, China).
For titration of infectious Ad production, the cells were collected with a cell scraper and pooled with the culture medium. The pooled samples were processed by freeze-thaw in liquid nitrogen for 3 times. The supernatants were collected by centrifugation at 5000 × g for 15 min and stored at −70 °C for titration analysis.
RT-PCR and real-time PCR
For RT-PCR studies, total RNA was extracted using TRIzol reagent (Life Technologies). One microgram RNA was reverse transcribed into cDNA using AMV reverse transcriptase. Real-time PCR was performed using SYBR Green PCR Master Mix (Q141-02/03, Vazyme, Nanjing, China) on an ABI 7300 PCR system (Applied Biosystems) and data was analyzed using the 2−ΔΔCt method to obtain relative abundance. GAPDH was used as an internal control for normalization. RNA levels from mock-treated samples of 3 h PI were assigned a value of 1 and used for comparison of RNA levels from corresponding samples. The primers used for hexon and fiber protein gene of Ad2 (accession number J01917) are as follows. Hexon gene: 5′-AACTTCCAGCCCATGAGC (forward) and 5′-TTGGCCCAGGTCTGTGAG (reverse). Fiber protein gene: 5′-ACCCCGTGTATCCATATGAC (forward) and 5′-ACGCGTAGAGAGAGAACTCC (reverse). GAPDH: 5′-ACAGTCAGCCGCATCTTCTT (forward) and 5′-ACGACCAAATCCGTTGACTC (reverse).
Flow cytometry study
Flow cytometry analysis was performed on FACS Calibur (BD Bio-sciences, San Jose, CA) to determine the levels of gene expression and delivery by Ad-EGFP transduction. The percentages of GFP positive cells and the mean fluorescence intensity (MFI) values were analyzed using the preinstalled software.
RNA interfering
The oligoes of small interfering RNA (siRNA) targeted human BRD4 were synthesized by GenePharma (Shanghai, China). For gene knockdown experiments, cells were plated in 12-well plates (Corning) 24 h before transfection. Cells were transfected using Lipofectamine-2000 and were used at 48–72 h after transfection for further experiments.
BRD4-siRNA #1: 5′-CUCCCUGAUUACUAUAAGATT and 5′-UCUUAUAGUAAUCAGGGAGTT;
BRD4-siRNA #2: 5′-GGAGAUGACAUAGUCUUAATT and 5′-UUAAGACUAUGUCAUCUCCTT;
BRD4-siRNA #3: 5′-GCACAAUCAAGUCUAAACUTT and 5′-AGUUUAGACUUGAUUGUGCTT.
Animal study
All experimental procedures were carried out strictly in accordance with the guide for the care and use of laboratory animals and the related ethical regulations instilled at Nanjing University Medical School. Female DBA/2J Nju (N000016) mice of 4–6 weeks of age were purchased from Model Animal Research Center of Nanjing University, and were housed under pathogen-free conditions on a 12/12 h light/dark cycle with free access to food and water.
The lymphocytic leukemia P388D1were transduced with Ad-EGFP for 2 h. The cells were then collected and washed 3 times with ice-cold PBS. The cells resuspended in PBS at 1 × 107 cells/ml were injected into the syngeneic DBA/2J mice peritoneally at 100 μl/mouse following a reported protocol41. The animals (3 per group) were then randomly grouped and then treated with a vehicle (control group), or JQ1 (3 and 10 mg/kg) by IP injection on day 2, 4, and 6 after inoculation. JQ1 freshly dissolved in DMSO was diluted with normal saline (final DMSO at approximately 1%). The ascetic cells were harvested on day 7 by rinsing the peritoneal cavity with 1.5 ml ice-cold PBS. The cells were sieved through 75-μm cell strainers, and red blood cells were removed by treatment with a red blood cell lysis buffer (Beyotime). After washing twice with PBS, the cells were resuspended in 0.5 ml ice-cold PBS and analyzed by flow cytometry for EGFP expression.
Statistical analysis
Each experiment was performed two or more times, with three technical replicates of each culture, condition or time point in each experiment. Data from one representative experiment are presented except otherwise stated. Data were analyzed by one-way ANOVA method using SPSS 17.0 software package.
Availability of materials and data statement
All data generated or analyzed during this study are included in this published article.
Use and care of experimental animals
The committee at Nanjing University Medical School approved the experimental procedures for use and care of laboratory animals (mice).
Results
JQ1 enhances Ad infection dose-dependently
To investigate whether BET bromodomain inhibition plays a role in Ad infection, A549 cells were treated with well-characterized BRD4 inhibitors 1 h prior to Ad2 infection. The inhibitors included JQ1, PFI-I, pan BD1/2 domain inhibitors, and RVX-208, a BD2 domain inhibitor. (−)-JQ1, an inactive enantiomer of JQ1, was included as a control. For a quick assay, the cells were infected with Ad2 at a MOI of 1 PFU per cell for 24 h. Viral infection was determined by detection of viral protein with immunoblotting assays. As shown in Fig. 1A, treatment with JQ-1 or PFI-1, inhibitors of pan-BD domains, resulted in significant increases in hexon and penton base (PB) production. Treatment with RVX-208, a BD2 domain selective inhibitor, also increased hexon and PB production. In contrast, treatment with (−)-JQ1 showed no enhancement effect on viral protein expression.
The effect of BRD4 inhibitors on Ad infection was further studied by treating Ad infected cells with varying amount of JQ1 since the target of this compound has been well characterized32. It has been reported that prolonged treatment with JQ1 at micromolar concentrations causes cell cycle arrests. We noticed that JQ1 at up to 500 nM concentrations did inhibit A549 growth after 48 h treatment (refer to M&M). We therefore used 30 to 500 nM concentrations for infection assays. As shown in Fig. 1B, JQ1 at 30 to 300 nM concentrations dose-dependently increased hexon and PB expression. In parallel experiments, JQ1 treatment also increased infectious virion production. There was an 1–2 log increase of infectious Ad in the samples treated with 100, 300, and 500 nM JQ1 (Fig. 1B). In a separate experiment, the samples were assayed at 12, 24 and 36 h post Ad infection. As shown in Fig. 1C, JQ1 treatment increased the yield of Ad production throughout the infection process. The enhancement effect of JQ1 on Ad infection was also demonstrated at mRNA levels. As shown in Fig. 1D, JQ1 treatment significantly increased hexon and fiber gene expression.
We also determined the time effect of JQ1 addition to Ad infection. In this regard, A549 cells were treated with 100 nM JQ1 prior to or during Ad2 infection. The samples were harvested at 36 h after infection for titration assay. As shown in Fig. 1E, addition of JQ1 at 2 h prior to (−2 h), during inoculation (0 h), or at 2, 4, and 6 h post Ad infection resulted in significant increase in infectious Ad2 production. The effect became less significant when JQ1 was added at 8–24 h PI.
Those results together showed that treatment with BRD4 inhibitors enhanced Ad infection.
JQ1 enhances Ad-mediated gene delivery
To expand these findings, we investigated whether JQ1 treatment affected Ad-mediated gene delivery using a replicative defective Ad. In this regard, A549 epithelial cells or Jurkat T lymphocytes were infected with an E1 deleted Ad5 that encodes an EGFP reporter gene (Ad-EGFP). The cells were then treated with JQ1 or remained untreated. EGFP expression was quantitatively determined by FACS analysis 24 h PI. As shown in Fig. 2A and B, JQ1 treatment increased EGFP expression. At 100 and 300 nM, JQ1 markedly increased the population of EGFP-expressing cells.
The findings were verified using an implanted tumor model42. To this end, the mouse leukemia P388D1 cells were infected with Ad-EGFP for 2 h. After washing with PBS, the infected cells or mock-treated control cells were resuspended in PBS and injected intraperitoneally to the syngeneic DBA2 mice. The animals were treated with JQ1 at 3 and 10 mg/kg on the 2rd, 4th, and 6th day post P388D1 inoculation, or mock-treated of the uninfected controls. On the 7th day, the cells from the peritoneal cavity were collected by rinse with PBS and EGFP expression was measured by flow cytometry. As shown in Fig. 2C, treatment with JQ1 at 3 and 10 mg/kg significantly increased EGFP expression compared with infected but mock-treated controls (Ad-EGFP con, p < 0.01). The results together showed that JQ1 treatment enhanced Ad-mediated gene delivery.
Requirement of BRD4 in Ad infection and JQ1 effect on Ad infection
HDAC inhibitors like FK228 and trichostatin A (TSA) were reported to increase Ad infection by promoting CAR expression43,44. We first investigated whether JQ-1 treatment altered CAR expression by immunoblotting for CAR expression. A549 cells expresses abundant CAR protein. JQ1 at 100 and 300 nM did not significantly affect CAR expression. Unlike TSA that caused histone-3 acetylation, JQ1 treatment did not cause histone-3 modifications (Fig. 3A).
JQ1 was originally developed as a specific BRD4 inhibitor that selectively interacts with the BD1 and BD2 domains and disrupts BRD4 interaction with acetylated lysine residues. We asked whether JQ1 promoted Ad infection through BRD4 protein since Brd4 release from chromatin is essential for its role transition from chromatin targeting to transcriptional regulation45. A549 cells were therefore treated with siRNA to suppress BRD4 expression. We identified 3 different siRNA that suppressed BRD4 expression effectively (Fig. 3B). Suppression of BRD4 expression not only blocked Ad infection but the JQ1 effect on Ad2 infection (Fig. 3C). The results suggested to us that both Ad infection and JQ1 effect on the infection required BRD4 protein expression.
Ad infection promotes BRD4 association with CDK9
BRD4 actively regulates gene transcription by recruiting positive transcription elongation factor b (P-TEFb) to gene promoters46,47. We tested whether JQ1 promoted Ad infection by through gene transcription. In this regard, we examined BRD4 association with P-TEFb. A549 cells were infected with Ad2 (10 PFU/cell) in the absence or presence of JQ1 for 5 h. The cells were then lysed and cell lysates were immunoprecipitated with anti-BRD4 antibody. P-TEFb and BRD4 association was detected by immunoblotting for CDK9, a subunit of P-TEFb, in the complexes. As shown in Fig. 4A, BRD4 and CDK9 had weak association in mock-infected samples. Ad infection resulted in increased detection of CDK9 in the anti-BRD4 immunocomplexes. Concurrently with an increase in Ad infection, BRD4-CDK9 association was also increased in Ad-infected and JQ1-treated samples. These results indicated that JQ1 promoted BRD4 and P-TEFb transcription complex formation.
To corroborate this conclusion, we first determined whether Ad infection required CDK9 activity by treating the cells with CDK9 inhibitors 1 h prior to infection. As shown in Fig. 4B, pretreatment of A549 cells with LDC000067, a selective inhibitor of CDK9 activity38, or with flavopiridol, an inhibitor of P-TEFb activity and subsequent RNA Pol II transcription39, significantly reduced hexon and PB protein synthesis. In addition, we found that LDC00067 treatment also blocked JQ1 enhancement effect on Ad infection (Fig. 4C).
Together, the study demonstrated that Ad infection required BRD4 expression. The study also showed that BRD4 inhibition can potentiate Ad-mediated gene delivery efficiency.
Discussion
We found that BRD4 inhibitors like JQ1 promoted Ad infection and Ad-mediated gene delivery. JQ1 is an inhibitor that blocks acetylated lysine interaction with the bromodomains of BRD4 and related proteins. As a multiple domain protein involved in cell regulation, BRD4 plays a critical role in gene transcription. We found that Ad infection induced BRD4 and CDK9 association, an event that was exacerbated by JQ1 treatment, suggesting that JQ1 likely regulates transgene expression by gene transcription. The conclusion was demonstrated using Ad2 and Ad5-based vectors, it is likely that the mechanism may apply to other types of adenoviruses since CDK9 inhibitors have been reported to inhibit replication of multiple DNA viruses35,48. This study therefore uncovers a pathway involved in Ad infection and Ad-mediated gene expression.
To establish infection in the host cell, adenovirus must rapidly express its early genes which are responsible for reconfiguring the cellular pathways and checkpoints, thus modifying the environment for optimal viral replication. Adenoviruses, like other DNA viruses, exist as nuclear episomes and are very likely to exploit epigenetic mechanisms to regulate biological activities during their life cycle21,49,50. Although the Ad2 E1A protein has a global effect on cellular transcription by directly impact on histone modifications22 and the activation of a subset of IFN-stimulated genes (ISGs)51, the assembly of a helper-dependent adenovirus DNA into chromatin for efficient gene expression is independent of viral DNA replication25,52. Similarly, we found that JQ1 also promoted gene delivery efficiency by an E1-deleted Ad, indicating transgene expression is independent of E1 gene function. We found that suppression of BRD4 expression or inhibition of P-TEFb activity blocked Ad infection, indicating that Ad exploits gene transcription mechanisms for productive infection and transgene expression.
BRD4 is a scaffold protein that recruits P-TEFb for gene transcription via increased Pol II phosphorylation by CDK9 subunit of P-TEFb. Notably, BRD4 interacts with P-TEFb via its P-TEFb interaction domain (PID), thereby stimulating its kinase activity and stimulating its phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase II for transcription elongation53,54. BRD4 has been shown to regulate virus infection with diverse mechanisms55. It interacts with papillomavirus E2 protein and tethers the viral DNA to host mitotic chromosomes for persistence of viral episomes in HPV-infected cells56; whereas the BRD4 PID suppresses the ability of HIV Tat transactivator by disrupting the interaction between the Tat and P-TEFb33. We showed here that BRD4 interacts with CDK9 and regulates Ad infection and Ad-mediated gene delivery. Further studies are required to delineate the mechanisms by which BRD4 utilizes to regulate adenovirus infection and transgene expression.
The Ad DNA is wrapped in nucleosomes and, as with cellular chromatin, changes in the epigenetic status of the histones impact upon regulation and expression of Ad encoded transgenes25. FK228, TSA, and butyrate, HDAC inhibitors, have been known to enhance Ad-mediated gene delivery efficiency. It was thought that FK228 and TSA enhanced Ad transduction through upregulation of the attachment receptor CAR43,57. However, the highest increase in transgene expression was achieved when non-toxic concentrations of FK228 were added immediately after transduction and was associated with increased histone H3 acetylation27,28, suggesting that FK228 works mainly by increasing transgene expression at the transcriptional levels. One of the major obstacles to success in gene therapy is transcriptional silencing of the DNA vector. The mechanisms underlying gene silencing/repression in mammalian cells are complex, but changes in chromatin structure and, in particular, histone modifications have been identified as a major factor in transcriptional regulation of endogenous genes. Those and our studies demonstrate epigenetic regulation pathways may be exploited for enhanced gene expression and transduction.
Adenovirus vectors have a number of advantages, including the adenovirus genome is well characterized and easy to manipulate and to produce to high purity, to name a few. In fact, among the almost 2,600 gene therapy clinical trials approved worldwide, a significant portion of the trials have been utilizing adenoviral vectors2. The nature that adenoviruses can drive robust and long-lasting immune responses of CD8 has led to vaccine designs using Ad vectors against pathogens like H5N1, Ebola, and Zika viruses58. The demonstration of JQ1 enhances Ad infection and Ad-mediated gene delivery may result in fewer vector doses for necessary gene expression, helping to alleviate disadvantages caused by Ad vectors for gene and cell-based therapies in the new era of personalized medicine.
References
Lee, C. S. et al. Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes Dis 4, 43–63, https://doi.org/10.1016/j.gendis.2017.04.001 (2017).
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M. & Abedi, M. R. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med, e3015, https://doi.org/10.1002/jgm.3015 (2018).
Lin, Q., Wang, D. G., Zhang, Z. Q. & Liu, D. P. Applications of Virus Vector-Mediated Gene Therapy in China. Hum Gene Ther 29, 98–109, https://doi.org/10.1089/hum.2017.238 (2018).
Sweeney, K. & Hallden, G. Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic Virother 5, 45–57, https://doi.org/10.2147/OV.S63047 (2016).
Thomas, C. E., Ehrhardt, A. & Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4, 346–358, https://doi.org/10.1038/nrg1066 (2003).
Wold, W. S. & Toth, K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13, 421–433 (2013).
Bergelson, J. M. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320–1323 (1997).
Tomko, R. P., Xu, R. & Philipson, L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94, 3352–3356 (1997).
Stewart, P. L. & Nemerow, G. R. Cell integrins: commonly used receptors for diverse viral pathogens. Trends Microbiol 15, 500–507, https://doi.org/10.1016/j.tim.2007.10.001 (2007).
Wickham, T. J., Mathias, P., Cheresh, D. A. & Nemerow, G. R. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 73, 309–319 (1993).
Baker, A. H., McVey, J. H., Waddington, S. N., Di Paolo, N. C. & Shayakhmetov, D. M. The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther 15, 1410–1416, https://doi.org/10.1038/sj.mt.6300206 (2007).
Bradshaw, A. C. et al. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. Plos Pathog 6, e1001142, https://doi.org/10.1371/journal.ppat.1001142 (2010).
Lopez-Gordo, E., Denby, L., Nicklin, S. A. & Baker, A. H. The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery. Expert Opin Drug Deliv 11, 1795–1813, https://doi.org/10.1517/17425247.2014.938637 (2014).
Bilsland, A. E., Spiliopoulou, P. & Evans, T. R. Virotherapy: cancer gene therapy at last? F1000Res 5, https://doi.org/10.12688/f1000research.8211.1 (2016).
Avgousti, D. C. et al. A core viral protein binds host nucleosomes to sequester immune danger signals. Nature 535, 173–177, https://doi.org/10.1038/nature18317 (2016).
VanOosten, R. L., Earel, J. K. Jr. & Griffith, T. S. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Therapy 13, 628–632, https://doi.org/10.1038/sj.cgt.7700939 (2006).
Komatsu, T., Haruki, H. & Nagata, K. Cellular and viral chromatin proteins are positive factors in the regulation of adenovirus gene expression. Nucleic Acids Res 39, 889–901, https://doi.org/10.1093/nar/gkq783 (2011).
Wong, C. M., McFall, E. R., Burns, J. K. & Parks, R. J. The role of chromatin in adenoviral vector function. Viruses 5, 1500–1515, https://doi.org/10.3390/v5061500 (2013).
Ma, J. et al. Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. Oncol Lett 13, 4868–4874, https://doi.org/10.3892/ol.2017.6069 (2017).
Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705, https://doi.org/10.1016/j.cell.2007.02.005 (2007).
Ferrari, R. et al. Reorganization of the host epigenome by a viral oncogene. Genome Res 22, 1212–1221, https://doi.org/10.1101/gr.132308.111 (2012).
Ferrari, R. et al. Adenovirus small E1A employs the lysine acetylases p300/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection. Cell Host Microbe 16, 663–676, https://doi.org/10.1016/j.chom.2014.10.004 (2014).
Ferrari, R., Berk, A. J. & Kurdistani, S. K. Viral manipulation of the host epigenome for oncogenic transformation. Nat Rev Genet 10, 290–294, https://doi.org/10.1038/nrg2539 (2009).
Yang, X. J., Ogryzko, V. V., Nishikawa, J., Howard, B. H. & Nakatani, Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382, 319–324, https://doi.org/10.1038/382319a0 (1996).
Ross, P. J., Kennedy, M. A. & Parks, R. J. Host cell detection of noncoding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic repression of transgene expression. J Virol 83, 8409–8417, https://doi.org/10.1128/JVI.00796-09 (2009).
Watanabe, T. et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Experimental Cell Research 312, 256–265, https://doi.org/10.1016/j.yexcr.2005.10.026 (2006).
Goldsmith, M. E. et al. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Molecular Cancer Therapeutics 6, 496–505, https://doi.org/10.1158/1535-7163.MCT-06-0431 (2007).
Danielsson, A., Dzojic, H., Rashkova, V., Cheng, W. S. & Essand, M. The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication. Plos One 6, https://doi.org/10.1371/journal.pone.0014700 (2011).
Taniguchi, Y. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int J Mol Sci 17, https://doi.org/10.3390/ijms17111849 (2016).
Dhalluin, C. et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491–496, https://doi.org/10.1038/20974 (1999).
Brand, M. et al. Small molecule inhibitors of bromodomain-acetyl-lysine interactions. ACS Chem Biol 10, 22–39, https://doi.org/10.1021/cb500996u (2015).
Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073, https://doi.org/10.1038/nature09504 (2010).
Bisgrove, D. A., Mahmoudi, T., Henklein, P. & Verdin, E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci USA 104, 13690–13695, https://doi.org/10.1073/pnas.0705053104 (2007).
Wang, X., Helfer, C. M., Pancholi, N., Bradner, J. E. & You, J. Recruitment of Brd4 to the human papillomavirus type 16 DNA replication complex is essential for replication of viral DNA. J Virol 87, 3871–3884, https://doi.org/10.1128/JVI.03068-12 (2013).
Ren, K. et al. An Epigenetic Compound Library Screen Identifies BET Inhibitors That Promote HSV-1 and -2 Replication by Bridging P-TEFb to Viral Gene Promoters through BRD4. Plos Pathog 12, e1005950, https://doi.org/10.1371/journal.ppat.1005950 (2016).
He, T. C. et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95, 2509–2514 (1998).
Luo, J. et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2, 1236–1247, https://doi.org/10.1038/nprot.2007.135 (2007).
Albert, T. K. et al. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br J Pharmacol 171, 55–68, https://doi.org/10.1111/bph.12408 (2014).
Chao, S. H. & Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276, 31793–31799, https://doi.org/10.1074/jbc.M102306200 (2001).
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55–63 (1983).
Mirabelli, C. K. et al. A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo. Cancer Res 48, 5447–5454 (1988).
Kim, D., Suh, Y., Lee, H. & Lee, Y. Immune activation and antitumor response of ar-turmerone on P388D1 lymphoblast cell implanted tumors. Int J Mol Med 31, 386–392, https://doi.org/10.3892/ijmm.2012.1196 (2013).
Pong, R. C. et al. Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application. Cancer Res 66, 8822–8828, https://doi.org/10.1158/0008-5472.CAN-05-4672 (2006).
Sachs, M. D. et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 11, 477–486, https://doi.org/10.1038/sj.cgt.7700726 (2004).
Ai, N. et al. Signal-induced Brd4 release from chromatin is essential for its role transition from chromatin targeting to transcriptional regulation. Nucleic Acids Res 39, 9592–9604, https://doi.org/10.1093/nar/gkr698 (2011).
Jang, M. K. et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 19, 523–534, https://doi.org/10.1016/j.molcel.2005.06.027 (2005).
Budhiraja, S. & Rice, A. P. Reactivation of latent HIV: do all roads go through P-TEFb? Future Virol 8, https://doi.org/10.2217/fvl.13.52 (2013).
Yamamoto, M. et al. CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses. The Journal of clinical investigation 124, 3479–3488, https://doi.org/10.1172/JCI73805 (2014).
Brockmann, D. & Esche, H. The multifunctional role of E1A in the transcriptional regulation of CREB/CBP-dependent target genes. Curr Top Microbiol Immunol 272, 97–129 (2003).
Milavetz, B. I. & Balakrishnan, L. Viral epigenetics. Methods Mol Biol 1238, 569–596, https://doi.org/10.1007/978-1-4939-1804-1_30 (2015).
Zemke, N. R. & Berk, A. J. The Adenovirus E1A C Terminus Suppresses a Delayed Antiviral Response and Modulates RAS Signaling. Cell Host Microbe 22, 789–800 e785, https://doi.org/10.1016/j.chom.2017.11.008 (2017).
Komatsu, T. & Nagata, K. Replication-uncoupled histone deposition during adenovirus DNA replication. J Virol 86, 6701–6711, https://doi.org/10.1128/JVI.00380-12 (2012).
Itzen, F., Greifenberg, A. K., Bosken, C. A. & Geyer, M. Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Res 42, 7577–7590, https://doi.org/10.1093/nar/gku449 (2014).
Quaresma, A. J. C., Bugai, A. & Barboric, M. Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb. Nucleic Acids Res 44, 7527–7539, https://doi.org/10.1093/nar/gkw585 (2016).
Zaborowska, J., Isa, N. F. & Murphy, S. P-TEFb goes viral. Bioessays 38(Suppl 1), S75–85, https://doi.org/10.1002/bies.201670912 (2016).
You, J., Croyle, J. L., Nishimura, A., Ozato, K. & Howley, P. M. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117, 349–360 (2004).
Kitazono, M., Goldsmith, M. E., Aikou, T., Bates, S. & Fojo, T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 61, 6328–6330 (2001).
Afkhami, S., Yao, Y. & Xing, Z. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol Ther Methods Clin Dev 3, 16030, https://doi.org/10.1038/mtm.2016.30 (2016).
Acknowledgements
The authors would like to thank staff members of Jiangsu Laboratory of Molecular Medicine for technical support. The work was partially supported by grants from Nanjing Bureau of Public Health (ZKX130391 to G.Y.), and Jiangsu Key Laboratory of Molecular Medicine (G.Y.) and NSFC (81071859 to E.L.).
Author information
Authors and Affiliations
Contributions
G.Y. and J.L. conceived the ideas, K.R. made the initial findings, B.L., J.L., M.L. and Y.Z. performed the experiments, E.L. contributed reagents, B.L. and E.L. analyzed the data, E.L. and G.Y. prepared the manuscript. All authors read and approved the final document.
Corresponding authors
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lv, B., Li, J., Li, M. et al. Enhancement of adenovirus infection and adenoviral vector-mediated gene delivery by bromodomain inhibitor JQ1. Sci Rep 8, 11554 (2018). https://doi.org/10.1038/s41598-018-28421-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-018-28421-x
This article is cited by
-
BET protein inhibition regulates cytokine production and promotes neuroprotection after spinal cord injury
Journal of Neuroinflammation (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.